|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...4445464748495051525354...6768» |
- | melphalan / Generic mfg., thalidomide / Generic mfg.
Enrollment change: Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 13, 2013
P3, N=122, Completed, Sponsor: Cigdem Sahinbas YILMAZ
N=100 --> 122
- | melphalan / Generic mfg., thalidomide / Generic mfg.
Trial completion: Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 13, 2013
P3, N=122, Completed, Sponsor: Cigdem Sahinbas YILMAZ
N=100 --> 122 Recruiting --> Completed
- | long-acting sequence-modified recombinant factor VIIa (BAY 866150) / Bayer
New P1 trial, IO biomarker: MATCHBOX: Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (clinicaltrials.gov) - Aug 11, 2013
P1, N=16, Completed, Sponsor: Bayer
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment open: RVD Lite: Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (clinicaltrials.gov) - Aug 11, 2013
P2, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- vatalanib (PTK787) / Novartis, Bayer
Trial termination, Post-transplantation: PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 8, 2013
P2, N=21, Terminated, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Completed --> Terminated; investigator letter from drug manufacturer stating animal studies showed increased risk of cancer which was an unknown adverse event
- HEOR: A Study of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures (clinicaltrials.gov) - Aug 7, 2013
P=N/A, N=120, Recruiting, Sponsor: DeNova Research
- New P4 trial, Surgery: ROTEM-2010: Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol (clinicaltrials.gov) - Aug 7, 2013
P4, N=49, Terminated, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Rituxan (rituximab) / Roche
Enrollment open: Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia (clinicaltrials.gov) - Aug 7, 2013
P=N/A, N=100, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital
Completed --> Terminated; investigator letter from drug manufacturer stating animal studies showed increased risk of cancer which was an unknown adverse event Active, not recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial completion: Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) (clinicaltrials.gov) - Aug 7, 2013
P2, N=15, Completed, Sponsor: Medical University of Vienna
Active, not recruiting --> Recruiting Recruiting --> Completed
- | IPH 2101 / Novo Nordisk, Innate
Trial completion: Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 7, 2013
P2, N=27, Completed, Sponsor: Innate Pharma
Recruiting --> Completed Active, not recruiting --> Completed
- | ImMucin (VXL100) / Vaxil Bio, BioVaxys
Trial completion: A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies (clinicaltrials.gov) - Aug 5, 2013
P1/2, N=15, Completed, Sponsor: Vaxil Therapeutics Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial initiation date, Surgery: Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (clinicaltrials.gov) - Aug 4, 2013
P=N/A, N=26, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Initiation date: Feb 2009 --> Aug 2009
- || New P3 trial, Journal: PETHEMA: Bortezomib (Velcade (clinicaltrials.gov) - Aug 1, 2013
P3, N=460, Recruiting, Sponsor: PETHEMA Foundation
- New P1 trial: Enzy-MagIC: The Effects of Enzymes and Flavonoids on Inflammation and Coagulation After Marathon (clinicaltrials.gov) - Aug 1, 2013
P1, N=160, Active, not recruiting, Sponsor: Technische Universit
- ||| Retacrit (epoetin alfa-epbx) / Stada, Norbitec, Pfizer
Trial completion: Biosimilar Retacrit (clinicaltrials.gov) - Aug 1, 2013
P=N/A, N=240, Completed, Sponsor: Hospira, Inc.
Initiation date: Feb 2009 --> Aug 2009 Active, not recruiting --> Completed
- Erivedge (vismodegib) / Roche
Enrollment closed: Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma (clinicaltrials.gov) - Jul 31, 2013
P1, N=38, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial termination: Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 30, 2013
P1/2, N=52, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; NCI stopped supplying fenretinide in November of 2012.
- Trial completion: Music Therapy on Nausea and Pain for Autologous Stem Cell (clinicaltrials.gov) - Jul 30, 2013
P=N/A, N=108, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Terminated; NCI stopped supplying fenretinide in November of 2012. Active, not recruiting --> Completed
- | sapanisertib (CB-228) / Calithera
Trial completion: Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jul 30, 2013
P1, N=39, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: An Observational Study of Early Coagulopathy, or Clotting Disorder, in Injured Patients (clinicaltrials.gov) - Jul 29, 2013
P=N/A, N=0, Withdrawn, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: An Observational Study of Early Coagulopathy, or Clotting Disorder, in Injured Patients (clinicaltrials.gov) - Jul 29, 2013
P=N/A, N=0, Withdrawn, Sponsor: Emory University
Recruiting --> Withdrawn N=930 --> 0
- Trial completion: Genetic Analysis of Gray Platelet Syndrome (clinicaltrials.gov) - Jul 29, 2013
P=N/A, N=123, Completed, Sponsor: National Human Genome Research Institute (NHGRI)
N=930 --> 0 Recruiting --> Completed
- Enrollment open, Metastases: CRUKD/12/003: A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies (clinicaltrials.gov) - Jul 29, 2013
P1, N=40, Recruiting, Sponsor: Cancer Research UK
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion: QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (clinicaltrials.gov) - Jul 29, 2013
P3, N=120, Completed, Sponsor: PETHEMA Foundation
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| bortezomib / Generic mfg.
New P3 trial: OPTIMRETREAT: Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (clinicaltrials.gov) - Jul 28, 2013
P3, N=240, Recruiting, Sponsor: Janssen-Cilag International NV
- Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics
Trial completion: rhFVIIa: A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (clinicaltrials.gov) - Jul 28, 2013
P1, N=15, Completed, Sponsor: rEVO Biologics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: IFM 2005-03: Treatment of Myeloma in Patients = 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning (clinicaltrials.gov) - Jul 25, 2013
P2, N=13, Completed, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed N=105 --> 13
- Enrollment closed: Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=26, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=105 --> 13 Recruiting --> Active, not recruiting
- || Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P3 trial: Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. (clinicaltrials.gov) - Jul 23, 2013
P3, N=90, Recruiting, Sponsor: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
- Onureg (azacitidine oral) / BMS
New P1 trial: Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (clinicaltrials.gov) - Jul 23, 2013
P1, N=18, Suspended, Sponsor: Celgene Corporation
- Enrollment closed: Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor (clinicaltrials.gov) - Jul 23, 2013
P2, N=28, Active, not recruiting, Sponsor: Thomas Jefferson University
Recruiting --> Active, not recruiting Withheld --> Active, not recruiting
- | bortezomib / Generic mfg.
Enrollment closed: Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients (clinicaltrials.gov) - Jul 22, 2013
P2, N=20, Active, not recruiting, Sponsor: University of Utah
Withheld --> Active, not recruiting Recruiting --> Active, not recruiting
- prednisone / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Combination therapy: Lenalidomide and Prednisone in Treating Patients With Myelofibrosis (clinicaltrials.gov) - Jul 22, 2013
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open: Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. (clinicaltrials.gov) - Jul 22, 2013
P3, N=90, Recruiting, Sponsor: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | imetelstat (GRN163L) / Geron
Enrollment closed: Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jul 22, 2013
P2, N=48, Active, not recruiting, Sponsor: Geron Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial termination: Thermogard™ Efficacy Trial (clinicaltrials.gov) - Jul 21, 2013
P=N/A, N=9, Terminated, Sponsor: Brooke Army Medical Center
Recruiting --> Active, not recruiting Enrolling by invitation --> Terminated; Difficulty in obtaining surrogate consent on critically ill subjects.
- Enrollment change: Thermogard™ Efficacy Trial (clinicaltrials.gov) - Jul 21, 2013
P=N/A, N=9, Terminated, Sponsor: Brooke Army Medical Center
Enrolling by invitation --> Terminated; Difficulty in obtaining surrogate consent on critically ill subjects. N=32 --> 9
- Leukine (sargramostim) / Partner Therap, plerixafor / Generic mfg.
Trial initiation date: Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (clinicaltrials.gov) - Jul 21, 2013
P2, N=48, Active, not recruiting, Sponsor: Washington University School of Medicine
N=32 --> 9 Initiation date: Nov 2010 --> Apr 2011
- Ninlaro (ixazomib) / Takeda
Enrollment change: Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 21, 2013
P1, N=24, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Initiation date: Nov 2010 --> Apr 2011 N=15 --> 24
- sapanisertib (CB-228) / Calithera
Enrollment change: Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jul 21, 2013
P1, N=39, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
N=15 --> 24 N=60 --> 39
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment change: S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2013
P3, N=198, Completed, Sponsor: Southwest Oncology Group
N=60 --> 39 N=500 --> 198
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion: S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2013
P3, N=198, Completed, Sponsor: Southwest Oncology Group
N=500 --> 198 Active, not recruiting --> Completed
- Trial completion: SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) (clinicaltrials.gov) - Jul 14, 2013
P=N/A, N=181, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P2 trial: Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma (clinicaltrials.gov) - Jul 10, 2013
P2, N=700, Recruiting, Sponsor: University of Alabama at Birmingham
- Trial completion: Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma (clinicaltrials.gov) - Jul 9, 2013
P=N/A, N=196, Completed, Sponsor: Azienda Ospedaliera San Giovanni Battista
Active, not recruiting --> Completed Not yet recruiting --> Completed
- melphalan / Generic mfg.
Enrollment change: Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases (clinicaltrials.gov) - Jul 9, 2013
P2, N=70, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Completed N=40 --> 70
- plerixafor / Generic mfg.
Biomarker, Enrollment open, Tumor microenvironment: Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jul 9, 2013
P1, N=16, Recruiting, Sponsor: Tufts Medical Center
N=40 --> 70 Not yet recruiting --> Recruiting
- | Fibryga (fibrinogen concentrate (human)) / Octapharma
Enrollment open: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Jul 8, 2013
P2, N=18, Recruiting, Sponsor: Octapharma
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment change, Post-transplantation: Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease (clinicaltrials.gov) - Jul 8, 2013
P1, N=12, Completed, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=42 --> 12
- Enrollment closed: A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (clinicaltrials.gov) - Jul 8, 2013
P1, N=25, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
N=42 --> 12 Recruiting --> Active, not recruiting